...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. (Special Issue: Advances in vaccine technology II 2008.)
【24h】

Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. (Special Issue: Advances in vaccine technology II 2008.)

机译：尽管存在Ad5免疫，新型5型腺病毒疫苗平台仍可诱导针对HIV-1 Gag，Pol，Nef的细胞免疫。 （特刊：疫苗技术的进步II，2008年。）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms in numerous animal and human clinical studies. The immune response induced by Ad5 vaccines can be mitigated due to pre-existing Ad5 immunity. We previously reported the use of a novel Ad5 platform to induce cellular immune responses (CMI) against HIV-1 Gag in Ad5 hyper immune mice. Here, the effectiveness of the Ad5 [E1-, E2b-] vaccine platform was evaluated using a triad mixture of HIV-1 Gag, Pol, and Nef as antigenic transgenes. Broad CMI was induced following vaccination with the HIV-1 expressing vectors in Ad5 naive and Ad5 immunized mice. A mixture of the three vaccines induced CMI against each transgene product even in the presence of hyper Ad5 immunity. These studies revealed that CMI responses to immunization with Ad5 [E1-, E2b-]-gag, Ad5 [E1-, E2b-]-pol or Ad5 [E1-, E2b-]-nef vectors were transgene specific and did not induce CMI responses against irrelevant antigens such as carcinoembryonic antigen (CEA), herpes simplex virus glycoprotein B (HSV), cytomegalovirus (CMV) or influenza virus antigens. We are evaluating this recombinant triad viral vector as an HIV-1 vaccine in a non-human primate model and the data indicate that the vaccine is worthy of clinical evaluation.
机译：重组腺病毒血清型5（Ad5）载体已在许多动物和人类临床研究中用作疫苗平台。由于已经存在Ad5免疫，因此可以缓解Ad5疫苗诱导的免疫反应。我们以前报道过使用新型Ad5平台在Ad5高免疫小鼠中诱导针对HIV-1 Gag的细胞免疫应答（CMI）。在这里，使用HIV-1 Gag，Pol和Nef的三联体混合物作为抗原转基因评估了Ad5 [E1-，E2b-]疫苗平台的有效性。在未经Ad5免疫和经Ad5免疫的小鼠中接种HIV-1表达载体后，诱导了广泛的CMI。即使在Ad5免疫力超强的情况下，三种疫苗的混合物也会诱导针对每种转基因产物的CMI。这些研究表明，用Ad5 [E1-，E2b-]-gag，Ad5 [E1-，E2b-]-pol或Ad5 [E1-，E2b-]-nef载体免疫的CMI反应是转基因特异性的，不会诱导CMI对无关抗原（例如癌胚抗原（CEA），单纯疱疹病毒糖蛋白B（HSV），巨细胞病毒（CMV）或流感病毒抗原）的免疫应答。我们正在非人灵长类动物模型中评估这种重组三联体病毒载体作为HIV-1疫苗，数据表明该疫苗值得临床评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号